PBH

+ Watchlist + Portfolio

Prestige Consumer Healthcare Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $51.68
52-Week Range: $42.62 – $71.07
Market Cap: $2.39B
P/E (TTM): 14.15
EPS (TTM): 3.57
Dividend Yield: —

Advanced Metrics

Price/Book: 1.25
PEG Ratio: 1.58
Return on Equity: 9.12%
Return on Assets: 4.58%
Gross Margin: 54.77%
Operating Margin: 20.83%
Profit Margin: 15.57%
Current Ratio: 3.23
Debt/Equity: 1.08
Total Debt: $2.07B
Free Cash Flow: $147.89M
Revenue Growth: 6.50%
Earnings Growth: -35.80%
Enterprise Value: $4.43B

PBH Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Revenue	$1.13B	$1.13B	$1.14B	$1.09B
Cost of Revenue	$502.43M	$500.91M	$503.30M	$493.13M
Gross Profit	$625.29M	$624.45M	$634.46M	$595.58M
Selling, General & Admin	$252.41M	$259.47M	$263.93M	$265.23M
Operating Expenses	$277.49M	$282.02M	$285.22M	$286.17M
Operating Income	$347.80M	$342.43M	$349.24M	$309.41M
EBITDA	$7.87M	$373.86M	$361.99M	$331.11M
Pretax Income	-$93.92M	$276.02M	$284.19M	$257.50M
Income Tax	-$11.61M	$66.69M	$69.58M	$67.19M
Net Income	-$82.31M	$209.34M	$214.60M	$190.30M
Diluted EPS	-1.65	4.17	4.29	3.91
Diluted Shares	49.89M	50.18M	50.08M	48.72M

PBH Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$58.49M	$46.47M	$97.88M	$63.87M
Receivables	$167.02M	$176.78M	$194.29M	$191.92M
Inventory	$162.12M	$138.72M	$147.71M	$159.13M
Current Assets	$391.74M	$375.04M	$448.33M	$431.48M
Total Assets	$3.35B	$3.32B	$3.40B	$3.49B
Current Liabilities	$160.72M	$117.05M	$106.62M	$120.92M
Long-Term Debt	$1.35B	$1.13B	$992.36M	$993.95M
Total Debt	$1.37B	$1.14B	$1.04B	$1.05B
Total Liabilities	$1.91B	$1.66B	$1.57B	$1.61B
Retained Earnings	$1.13B	$1.34B	$1.56B	$1.75B
Shareholders' Equity	$1.45B	$1.66B	$1.83B	$1.89B
Working Capital	$231.03M	$258.00M	$341.70M	$310.56M
Net Debt	$1.29B	$1.08B	$894.47M	$933.07M

PBH Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	$229.72M	$248.93M	$251.51M	$257.63M
Capital Expenditure	-$7.78M	-$9.55M	-$8.22M	-$11.18M
Free Cash Flow	$221.93M	$239.38M	$243.29M	$246.45M
Depreciation & Amortisation	$32.63M	$30.68M	$30.17M	$31.27M
Stock-Based Compensation	$12.40M	$14.01M	$11.16M	$10.84M
Investing Cash Flow	-$11.58M	-$20.11M	-$17.45M	-$136.84M
Financing Cash Flow	-$185.85M	-$241.01M	-$182.07M	-$156.06M
Share Repurchases	-$50.00M	-$25.00M	-$51.51M	-$156.28M
Net Change in Cash	$32.29M	-$12.20M	$51.99M	-$35.28M

PBH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$296.52M	$249.53M	$274.11M	$283.44M	$281.62M
Cost of Revenue	$126.51M	$109.20M	$122.53M	$126.08M	$135.32M
Gross Profit	$170.01M	$140.33M	$151.58M	$157.37M	$146.30M
Selling, General & Admin	$64.05M	$63.39M	$66.74M	$69.73M	$65.37M
Operating Expenses	$69.12M	$68.58M	$71.91M	$74.88M	$70.81M
Operating Income	$100.89M	$71.76M	$79.67M	$82.49M	$75.49M
EBITDA	$91.97M	$79.65M	$86.83M	$80.08M	$84.55M
Pretax Income	$73.96M	$61.78M	$69.13M	$61.81M	$64.77M
Income Tax	$23.83M	$14.31M	$26.92M	$15.12M	$10.84M
Net Income	$50.13M	$47.47M	$42.21M	$46.70M	$53.93M
Diluted EPS	1.00	0.95	0.86	0.97	1.13
Diluted Shares	50.06M	49.83M	49.26M	48.09M	47.69M

PBH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$97.88M	$139.50M	$119.11M	$62.37M	$63.87M
Receivables	$194.29M	$168.41M	$199.00M	$190.46M	$191.92M
Inventory	$147.71M	$153.13M	$159.00M	$163.59M	$159.13M
Current Assets	$448.33M	$480.52M	$497.41M	$433.43M	$431.48M
Total Assets	$3.40B	$3.43B	$3.44B	$3.49B	$3.49B
Current Liabilities	$106.62M	$109.67M	$134.60M	$139.56M	$120.92M
Long-Term Debt	$992.36M	$992.75M	$993.15M	$1.03B	$993.95M
Total Debt	$1.04B	$1.04B	$1.04B	$1.08B	$1.05B
Total Liabilities	$1.57B	$1.58B	$1.62B	$1.67B	$1.61B
Retained Earnings	$1.56B	$1.60B	$1.65B	$1.69B	$1.75B
Shareholders' Equity	$1.83B	$1.86B	$1.82B	$1.83B	$1.89B
Working Capital	$341.70M	$370.85M	$362.81M	$293.87M	$310.56M
Net Debt	$894.47M	$853.25M	$874.04M	$971.17M	$933.07M

PBH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$61.85M	$79.01M	$57.49M	$78.29M	$42.84M
Capital Expenditure	-$3.48M	-$838.00K	-$2.10M	-$3.03M	-$5.21M
Free Cash Flow	$58.37M	$78.17M	$55.38M	$75.26M	$37.63M
Depreciation & Amortisation	$7.25M	$7.67M	$7.66M	$7.59M	$8.35M
Stock-Based Compensation	$2.73M	$3.68M	$1.77M	$2.74M	$2.65M
Investing Cash Flow	-$3.48M	-$1.94M	-$2.93M	-$128.56M	-$3.41M
Financing Cash Flow	-$11.49M	-$36.28M	-$74.95M	-$6.73M	-$38.10M
Share Repurchases	-$11.31M	-$34.77M	-$75.00M	-$45.82M	-$690.00K
Net Change in Cash	$46.88M	$40.79M	-$20.39M	-$57.01M	$1.33M

Market Snapshot

About

Prestige Consumer Healthcare Inc. develops, manufactures, and markets over-the-counter healthcare and household cleaning products. The company owns brands including Monistat, Clear Eyes, Chloraseptic, Dramamine, Luden throat drops, Compound W, and Debrox, distributed primarily in North America and Australia.